You are here

Vfend Special Investigation For Pediatric - Observational

Last updated on April 11, 2018

FOR MORE INFORMATION
Study Location
XXXXXXX
Osaka, , Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pediatric Safety and Effectiveness
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-15
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who is under 15 years old and deep mycosis infection.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have been previously enrolled in this study. -

NCT02554656
Pfizer
Recruiting
Vfend Special Investigation For Pediatric - Observational

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT02499120
All Genders
18+
Years
Multiple Sites
Androgen Receptor Positive Triple Negative Breast Cancer Advanced
NCT01889238
Females
18+
Years
Multiple Sites
Candidemia, Peritonitis) Other Forms of Candida Infections(Intra-abdominal Abscess
NCT00802854
All Genders
0+
Years
Multiple Sites
Vfend Special Investigation For Pediatric - Observational
Vfend Special Investigation For Pediatric
Examine the safety and effectiveness of Vfend [voriconazole] for pediatric under general clinical practices.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
The subjects who have been treated with voriconazole for severe mycosis
Pediatric Safety and Effectiveness
Not Provided
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
September 2018
September 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who is under 15 years old and deep mycosis infection.

Exclusion Criteria:

  • Patients who have been previously enrolled in this study. -
Sexes Eligible for Study: All
up to 15 Years   (Child)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Japan
 
 
NCT02554656
A1501100
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now